Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.

The Journal of clinical investigation - 1 Nov 2013

Court Helen, Amoyel Marc, Hackman Michael, Lee Kyoung Eun, Xu Ruliang, Miller George, Bar-Sagi Dafna, Bach Erika A, Bergö Martin O, Philips Mark R

Abstract excerpt

RAS is the most frequently mutated oncogene in human cancers. Despite decades of effort, anti-RAS therapies have remained elusive. Isoprenylcysteine carboxylmethyltransferase (ICMT) methylates RAS and other CaaX-containing proteins, but its potential as a target for cancer therapy has not been fully evaluated. We crossed a Pdx1-Cre;LSL-KrasG12D mouse, which is a model of pancreatic ductal adenocarcinoma (PDA),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma in Situ
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Metaplasia

Share to Mice, 129 Strain

Share to Pancreas

Share to Pancreatic Neoplasms

Share to Protein Methyltransferases

Share to Receptor, Notch1

Source

Open in PubMed Open full text

Identifiers

PMID: 24216479
DOI: 10.1172/JCI65764
PMCID: PMC3809775

Genes

ICMT
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.PMID 24216479Read ↗

Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.Semantic proximity Read ↗

A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary BiologySemantic proximity Read ↗

Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal.Semantic proximity Read ↗

Hedgehog/Ras interactions regulate early stages of pancreatic cancer.Semantic proximity Read ↗

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSemantic proximity Read ↗

Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis.Semantic proximity Read ↗

DNA methylation memory of pancreatic acinar-ductal metaplasia transition state altering Kras-downstream PI3K and Rho GTPase signaling in the absence of Kras mutation.Semantic proximity Read ↗

Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.Semantic proximity Read ↗

Loss of Jag1 cooperates with oncogenic Kras to induce pancreatic cystic neoplasms.Semantic proximity Read ↗

Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic NeoplasiaSemantic proximity Read ↗

Atypical Protein Kinase Cι Is Required for Bronchioalveolar Stem Cell Expansion and Lung TumorigenesisSemantic proximity Read ↗

Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.